May 25, 2006
The Bill & Melinda Gates Foundation has announced a new $104 million grant to the Global Alliance for TB Drug Development in order to:
- Advance moxifloxacin into Phase III trials, with the goal of demonstrating its effectiveness for TB by 2010;
- Pursue nine pre-clinical projects and identify the best of these compounds for clinical studies;
- Work with policymakers, TB treatment providers and advocates to ensure that new TB drugs will be adopted and made accessible in developing countries;
- Analyze drug market conditions and compliance issues to ensure the rapid adoption of a new drug regimen once it is shown to be effective.
CGD blog posts reflect the views of the authors, drawing on prior research and experience in their areas of expertise. CGD is a nonpartisan, independent organization and does not take institutional positions.